Kubota Pharmaceutical Holdings Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥8M | ¥40M | ¥27M | ¥21M |
| Gross Profit | ¥2M | ¥28M | ¥22M | -¥5M |
| Operating Income | -¥2,038M | -¥1,504M | -¥1,345M | -¥895M |
| Pretax Income | -¥2,004M | -¥1,480M | -¥1,325M | -¥675M |
| Net Income | -¥2,016M | -¥1,490M | -¥1,333M | -¥676M |
| EPS | -¥40.92 | -¥26.79 | -¥23.65 | -¥10.59 |
| Operating Margin | -24,691.30% | -3,770.67% | -4,948.66% | -4,194.31% |
| Balance Sheet | ||||
| Total Assets | ¥4,420M | ¥3,017M | ¥1,542M | ¥1,979M |
| Total Equity | ¥3,950M | ¥2,647M | ¥1,390M | ¥1,814M |
| Total Liabilities | ¥470M | ¥370M | ¥152M | ¥166M |
| Cash | ¥4,049M | ¥2,768M | ¥1,455M | ¥1,919M |
| Interest-bearing Debt | ¥343M | ¥253M | ¥63M | ¥128M |
| Equity Ratio | 89.36% | 87.73% | 90.13% | 91.63% |
| D/E Ratio | 0.09 | 0.10 | 0.05 | 0.07 |
| Cash Flow | ||||
| Operating CF | -¥2,087M | -¥1,336M | -¥1,195M | -¥583M |
| Investing CF | ¥505M | -¥45M | -¥43M | -¥4M |
| Financing CF | ¥1,447M | ¥97M | -¥88M | ¥1,066M |
| Free CF | -¥2,145M | -¥1,402M | -¥1,245M | -¥594M |
| Efficiency | ||||
| ROE | -51.04% | -56.28% | -95.91% | -37.28% |
| ROA | -45.61% | -49.38% | -86.44% | -34.16% |
Latest IR Information
-
2026 February Interim Financial Results Presentation
Describe the overview of the second-quarter results for the 2026 fiscal year and the outlook going forward. Mentions trends in revenue and profit, movements by major segments, progress in the R&D pipeline, and potential changes to capital policy and dividend...
Read more -
Notice of exercise completion of stock acquisition rights through third-party allotment
Exercise completion of 450,000 stock acquisition rights. Includes details on issued shares, number of stock acquisition rights, exercise date, and the counterparty’s name.
Read more -
Notice of milestone consideration receipt related to the manufacture of emixustat hydrochloride
Read more
Latest News (5 items)
Company Information
About
Kubota Pharmaceutical Holdings Co., Ltd. engages in the pharmaceutical and medical device business worldwide. The company offers eyeMO, a remote retinal monitoring device for home-based and patient self-monitoring optical coherence tomography; and a NASA high-res version OCT device. It also provides Emixustat HCI compounds for Stargardt disease indications in Phase 3 clinical trials, as well as proliferative diabetic retinopathy and diabetic macular edema in Phase 2 clinical trials. The company was founded in 2002 and is headquartered in Minato, Japan.
